Study related to the active ingredients of tongguang vine injection in the treatment of ovarian cancer

Title : Study related to the active ingredients of tongguang vine injection in the treatment of ovarian cancer

Abstract:

Ovarian cancer is one of the three most common cancers of the female reproductive system, with the mortality rate ranking first among gynecological malignancies. Due to its special anatomical location, 75% of patients are already in advanced stage at the time of diagnosis, and the 5-year survival rate is only 29%. Tong Guan Vine is the dried vine stem of Tong Guan Vine in the genus Milkvetch, family Romeraceae, containing a variety of steroidal bitter ester glycosides, polysaccharides, alkaloids, resins and other active ingredients, with the efficacy of relieving cough and asthma, expectorant, purging heat and detoxification, and its preparation Tong Guan Vine Injection has been widely used in clinical antitumor, but the specific antiovarian cancer active substances and the mechanism of molecular action is not yet fully clarified. In this paper, we analyzed the chemical composition of Tongguan vine injection, combined with in vivo cellular experiments and in vitro transplantation tumor experiments in nude mice, to evaluate the antitumor effect of Tongguan vine injection on ovarian cancer, to explore the pharmacodynamic mechanism of its antitumor effect, and to find out the active ingredients of Tongguan vine injection in the treatment of ovarian cancer. The results showed that Tongguan vine injection and its active ingredients could effectively inhibit the value-added of tumor cells, migrate and promote the apoptosis of tumor cells in cell experiments. In nude mice tumor formation experiment, Tongguan vine injection and its active ingredients can effectively inhibit tumor growth, regulate tumor-related pathways, and exert anti-tumor effects. And the molecular biology experiment verified the mechanism of anti-ovarian cancer, providing theoretical support for clinical research.

Biography:

Wu Changlan  will graduate from South-Central Minzu University in June 2025 with a Master's Degree in Biomedical Engineering, specifically in the area of membrane ion channels and drug discovery and development. She mainly uses animal, molecular and cellular experiments to elucidate the mechanism of action of active ingredients in Chinese medicine.Her master's supervisor is Chen Su. Chen Su has completed his PhD from Beijing University of Technology and as Visiting scholar from University of Queensland, Australia. She is the Professor of South-central Minzu University. She has published more than 40 papers in reputed journals and has been serving as served as a reviewer for journals such as Planta Medica and Phytotherapy Research.